ROCKVILLE, Md., March 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
A live webcast of Synthetic Biologics’ presentation can be accessed by logging onto the web at http://wsw.com/webcast/roth29/syn. After the presentation, a replay will be archived and accessible for 60 days at the same website.
Mr. Riley, as well as Synthetic Biologics’ Senior Vice President, Clinical & Regulatory Affairs, Joe Sliman, MD, MPH, will be available to participate in one-on-one meetings with investors who are registered to attend the conference. In order to register, please contact your ROTH representative.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), and in collaboration with Intrexon Corporation (NYSE: XON), a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-27th-annual-roth-conference-300044070.html
SOURCE Synthetic Biologics, Inc.
Released March 3, 2015